Geneva, May 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123930) titled 'Safety and Tolerability of Au-TMP Nanoparticles in Combination With Radiotherapy for Patients With Advanced Melanoma Receiving Anti-PD-1 Therapy' on May 1.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: West China Hospital, Sichuan University

Condition: Advanced melanoma

Recruitment Status: Not Recruiting

Phase: 1

Date of First Enrollment: 2026-05-01

Target Sample Size: Dose-Escalation Cohorts:9;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=321456

Disclaimer: Curated by HT Syndication....